
Agilent (A) shares have risen 5.4% since their last earnings report, outperforming the S&P 500, despite analyst estimates trending downward and the company holding a subpar aggregate VGM Score of D. Notably, Zacks maintains a #2 (Buy) rank for Agilent, anticipating above-average returns, which presents a divergence between recent stock momentum and underlying fundamental estimate revisions.
Agilent Technologies (A) presents a conflicting investment profile, characterized by a significant divergence between recent market performance and underlying fundamental signals. The stock has appreciated 5.4% over the past month, outperforming the S&P 500. However, this positive momentum is directly at odds with analyst sentiment, as earnings estimates have been broadly trending downward. Furthermore, the company's quantitative metrics are notably weak, with a 'D' for its Growth and Momentum Scores and an equally subpar aggregate VGM Score of 'D'. This negative fundamental picture is contradicted by a Zacks Rank #2 (Buy), which projects above-average returns in the near term. For context, industry peer Medtronic (MDT) also saw a 4.6% gain but received a Zacks Rank #4 (Sell) that aligns more logically with its negative estimate revisions and a flat forward earnings outlook, despite having a superior 'B' VGM score. The disparity in Agilent's case—strong price action and a buy rating versus deteriorating estimates—suggests that the market has not yet priced in the potential for weaker future performance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment